We are investigating the fairness of the proposed sale of Nuvalent, Inc. (Nasdaq: NUVL) (“NUVL”) for $124.00 per share in cash to GSK in a tender offer.
The sale price is well below the price targets of multiple Wall Street analysts before the deal was announced, including:
- Colleen Kusy of Robert W. Baird ($158.00 price target)
- Bradley Canino of Guggenheim ($151.00 price target)
- Gregory Renza of Truist Financial ($140.00 price target)
- David Dai of UBS ($138.00 price target)
- Laura Prendergast of Stifel Nicolaus ($135.00 price target)
- John Newman of Canaccord Genuity ($126.00 price target)
If you remain a NUVL shareholder and have concerns about the fairness of the sale price, you may contact our firm to discuss your legal rights at no charge by completing and submitting the form below.
“We are investigating whether the NUVL board of directors acted in the best interests of NUVL shareholders in recommending the merger,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter. “This includes whether the sale price is fair to NUVL shareholders, and whether all material information regarding the transaction has been fully disclosed, including all conflicts.”